中文

/

English

创新研发

GenScript ProBio and Neoletix signed a letter of intent on clinical and commercial production of rFⅧ

https://www.prnewswire.com/news-releases/genscript-probio-and-neoletix-signed-a-letter-of-intent-on-clinical-and-commercial-production-of-recombinant-human-coagulation-factor-viii-301302719.html?tc=eml_cleartime

分享到：

北京经济技术开发区亦创高科科技园

13520295482

info@neoletix.com

至爱生命庄亚生物致力于凝血、抗凝血及抗肿瘤药物开发